YoheiDoiMD
Infectious Disease • Pittsburgh, PAAssistant Professor, Medicine, University of Pittsburgh School of Medicine
Are you Dr. Doi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3601 5th Ave
# Falk
Pittsburgh, PA 15213Phone+1 412-648-6401Fax+1 412-648-6399
Summary
- Dr. Yohei Doi, MD is an infectious disease specialist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is affiliated with UPMC Presbyterian Shadyside and UPMC Magee-Womens Hospital.
Education & Training
UPMC Medical EducationFellowship, Infectious Disease, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2003 - 2005
Nagoya University - School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2005 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Gram Negative Bacteremia, Risk Factors for Failure of Therapy Start of enrollment: 2005 Apr 01
- Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria Start of enrollment: 2006 Jan 01
- Community - Associated Extended-spectrum Beta-lactamases (ESBL) Start of enrollment: 2006 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Evolutionary loss of an antibiotic efflux pump increasesquorum sensing mediated virulence.Sheryl E Fernandes, Humberto Ortega, Mylene Vaillancourt, Anna Clara M Galdino, Aleksandr Stotland
Research Square. 2024-11-12 - Characterization offrom subjects with diffuse panbronchiolitis.Charles M Met, Casey E Hofstaedter, Ian P O'Keefe, Hyojik Yang, Dina A Moustafa
Microbiology Spectrum. 2024-11-05 - Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections.Angelique E Boutzoukas, Natalie Mackow, Abhigya Giri, Lauren Komarow, Carol Hill
The Journal of Antimicrobial Chemotherapy. 2024-11-04
Press Mentions
Fujita Health University Favipiravir Trial Evidences No Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?July 11th, 2020- WHO Studies File International Each Day Coronavirus Circumstances Improve: LiveJuly 10th, 2020
No Pause in Coronavirus Trial for Avigan, Japan's Lead Researcher SaysMay 20th, 2020- Join now to see all
Grant Support
- Multidrug-Resistant Acinetobacter BaumanniiNational Institute Of Allergy And Infectious Diseases2009–2010
- Epidemiology Of Community-Associated, Esbl-Producing Escherichia ColiNational Institute Of Allergy And Infectious Diseases2009–2010
Professional Memberships
- Member
